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for Food Technology, National Food Institute, Technical University of Denmark, Søborg, Denmark, Email 8 address: kals@food.dtu.dk 9 1. Introduction 46 Humans are exposed to silver from various sources. Silver is an antibacterial agent in the treatment of burn 47 wounds, scalds, ulcers, and in the prophylaxis of neonatal conjunctivitis (Moore et al., 2015; Polk, 1966) . 48
Medical devices, such as catheters, transdermal drug delivery devices, acupuncture needles, and sutures, also 49 contain silver (Lansdown, 2006) . Other sources of silver exposure include amalgam fillings, self-medication, 50 jewelry, deodorants, functional textiles, coins, tableware, coatings in refrigerators, and the workplace (Fluhr 51 et al., 2010; Hipler et al., 2006; Miller et al., 2010; Nakane et al., 2006; Rongioletti et al., 1992; Schröder et 52 al., 2012; Stefaniak et al., 2014; Tomi et al., 2004; Wollina et al., 2006; Yamamoto et al., 2012) . Physical 53 forms of silver are ions and metal. The metal encompasses nanoparticles and nanocrystalline coatings. The 54 aim of this paper is to review the toxicity of silver following in vivo dermal and mucosal surface exposure. 55
The endpoints genotoxicity and carcinogenicity are considered of very high severity. Therefore, genotoxicity 56 and carcinogenicity data obtained using all in vivo exposure pathways (not only dermal and mucosal 57 exposure) are considered as are in vitro data. In order to obtain all relevant journal articles for the current 58 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 (Clemente et al., 1977) , 7 µg/day, in Canadian women (Gibson and Scythes, 1984) and 27 µg/day in a 71 population from the United Kingdom (Hamilton et al., 1973) . WHO has reported that silver is occasionally 72 found in drinking water at concentrations above 5 µg/L, and that daily intakes of silver are approximately 7 73 µg/person (WHO, 2008) . Data on absorption of silver over intact skin, mucosal surfaces, and compromised 74 skin are presented in Figure 1 and detailed in the following sections. Silver was not absorbed into the blood when human intact skin was exposed to 100 g of 1% silver 89 sulfadiazine 1 cream per day for 2 weeks (~14 mg silver/kg bw/day) (Coombs et al., 1992) . In guinea pigs, 2 90 mL of 0.24 M silver nitrate applied to 3.1 cm 2 of intact skin (~138 mg silver/kg bw) resulted in an absorption 91 of silver ions of less than 1% (Wahlberg, 1965) . In rats, a 1% silver sulfadiazine was applied to intact skin on 92 5 consecutive days (~20 mg silver/kg bw/day), yielding a serum level of 1.5 µg silver/L. Controls had a level 93 of 1.2 µg silver/L. Levels of silver in liver, kidney, spleen, bone, and brain were equal in control and exposed 94 animals (Sano et al., 1982) . Silver from silver nanoparticles in the size range of tens to hundreds of 95 nanometer in diameter penetrated into the human stratum corneum. Here it formed aggregates in deeper 96 layers, likely slowing down penetration of silver into viable skin layers (Bianco et al., 2016) . 97 98 2.1.2. Absorption of silver over mucosal surfaces 99 Silver has been described to cross the human eye mucosa following administration of silver nitrate 100 (Karcioglu and Caldwell, 1985) and silver cyanide (Schlötzer-Schrehardt et al., 2001) . For silver cyanide, 101 this phenomenon has also been observed in rats (Rungby, 1986) . Silver nitrate applied by intrauterine 102 administration was fatal in one human, indicating uptake over the uterine mucosal surface. The dose was 7 g 103 of silver nitrate (~64 mg silver/kg bw). In the woman this resulted in a blood level of 3480 µg silver/L, a 104 urine level of 380 µg silver/L and in organ levels of: 8180 µg silver/kg (liver, tissue wet weight), 6100 105 (kidney), 2000 (heart), 148 (brain), 1400 (muscle), 140 (fat tissue), and 8200 (placenta). In the fetus organ 106 1 Silver sulfadiazine is a topical antibacterial agent in which the silver and sulfadiazine moieties are pharmaceutically active (Fox, 1975) . The literature does not often specify if the mass concentration of SSD is weight/weight (w/w). However, for several products, the manufacturers' descriptions have included the (w/w) designation, for example, the Flamazine and Silvadene creams (Pfizer, 2016; Smith_&_Nephew_Healthcare_Ltd, 2011) . In addition, the (w/w) designation is in compliance with FDA recommendations for reporting mass concentrations in topical creams (FDA, 2017) .
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A C C E P T E D ACCEPTED MANUSCRIPT 6 levels were 840 µg silver/kg (liver, tissue wet weight), 400 (lung), 150 (muscle) and less than 10 µg/kg in 107 kidney, heart and brain. The latter findings suggest that silver is able to pass the placenta (Reinhardt et al., 108 1971) . A woman used silver-containing 2 nose drops for 10 years had a serum level of 63 µg silver/L, 109 indicating that silver is absorbed over the nasal mucosa (Van de Voorde et al., 2005) . 110 111 2.1.3. Absorption of silver over skin compromised by burn wounds 112 An 18-year-old man with a burn wound covering 96% of the body surface was treated with silver nitrate, 113
resulting in blood and skin levels of 120 µg silver/L and 1,250 mg silver/kg, respectively (Bader, 1966) . 114
Silver sulfadiazine application to burn wounds resulted in serum levels of silver in the range of 2 to more 115 than 200 µg/L and, in a deceased patient, silver was detected in the liver and kidney (Coombs et al., 1992) . 116
Burn patients administered silver sulfadiazine cream had a mean plasma level of 200 µg silver/L, and silver 117 was detected in the corneal tissue, liver, and kidney at levels of 970, 14, and 0.2 µg silver/g tissue, 118
respectively (Wan et al., 1991) . When silver sulfadiazine cream was applied to rats, the absorption was low 119 for a) normal skin (1.2 µg silver/L in serum), b) superficial dermal burn wound with blister (3.4 µg/L) and c) 120 deep dermal wound (1.5 µg/L); notably, if the superficial dermal wound had the blister removed, silver in 121 serum increased considerably (13 µg/L). A control group with no silver sulfadiazine application had a level 122 of 1.2 µg silver/L. In all groups, silver was detected in liver, kidney, spleen, bone, and brain (Sano et al., 123 1982) . 124 Nanocrystalline silver dressing 3 was applied to 6 patients with burns. A maximum serum level of 200 125 µg silver/L was measured at 9 days of treatment (Moiemen et al., 2011) . Thirty burn patients treated with the 126 dressing for 11 days had a median serum level of silver of 57 µg/L (Vlachou et al., 2007) . In another burn 127
wound case, the application of nanocrystalline silver dressing for 7 days (~35 mg silver/kg bw/day 4 ) resulted 128 in a plasma level of 107 µg silver/L (Trop et al., 2006) . In rats, dressings containing either silver sulfate or 129 nanocrystalline silver were applied to burn wounds and changed every week. In weeks 3 and 6, the blood 130 levels of silver were 136 and 33 µg/kg for silver sulfate and 62 and 168 µg/kg for nanocrystalline silver, 131 respectively. In the spleen, kidney, and liver, the silver level was higher for nanocrystalline silver, compared 132 with silver sulfate. Silver was also detected in the brain, testis, lung, heart, and muscle (Pfurtscheller et al., 133 2014) . 134 135 2.1.4. Absorption over skin compromised by other wounds and scalding 136 A 64-year-old woman was treated for leg ulcers with 100 g 1% silver sulfadiazine cream every week. After 137 treatment for 18 months, the blood level of silver was 38 µg/L (Maitre et al., 2002) . A 61 year-old woman 138 was treated for ulcers with 200 g silver sulfadiazine cream per day (~9 mg silver/kg bw/day). After 3 weeks 139 of treatment, the level of silver in blood was 194 µg/L (Chaby et al., 2005) . In 40 patients with chronic 140 wounds treated with different silver preparations, serum silver was observed to correlate to wound area 141 (Brouillard et al., 2018) . Pigs with scalds were applied 1 g of 1% silver sulfadiazine cream for 48 h; 142 Absorption of silver was less than 1%, but silver was detected in the eye, kidney, lung, stomach, adrenal, 143 aorta, muscle, spleen, intestine, thyroid, and brain (Lazare et al., 1974) . 144 145 2.1.5. Summary of the absorption of silver over skin and mucosal surfaces 146 Intact skin is observed to pose an efficient barrier against silver. Mucosal surfaces, including in the eye, are 147 observed to pose a less efficient barrier. When skin is compromised by burns, scalds, or wounds, it is 148 observed to be more penetrable; specifically, one study showed that uptake highly increased if the wound 149 blister was removed. Following exposure, silver has been detected in all organs investigated. Detection in the 150 brain indicates that silver crosses the blood-brain barrier. Dermal metabolism of silver has been reported. Nanocrystalline silver and silver nitrate were administered to 154 the skin of pigs. With the nanocrystalline form, silver at molecular weights corresponding to Ag, AgO, AgCl, 155 AgNO 3 , Ag 2 O, and so-called silver clusters (Ag 2-6 ) were measured in the epidermis. With silver nitrate 156 dosage, only AgO, AgCl, AgNO 3 , and Ag 2 O were observed (Nadworny et al., 2010) . A substantial number 157 of studies have described the deposition of silver as particles in the body (Supplementary material tables S1 158 and S2). Deposited particles observed in the skin were of brown or brown-black color at the microscopic 159 level and differed in sizes: in the range of 10 to 1,000 nm (Kakurai et al., 2003; Matsumura et al., 1992; Sato 160 et al., 1999; Suzuki et al., 1993; Tanita et al., 1985) . In the eyes, the sizes of deposited particles ranged from 161 15 to 35 nm (Karcioglu and Caldwell, 1985; Schlötzer-Schrehardt et al., 2001) . The anatomical localization 162 of deposited silver-containing particles in the skin were especially a) in the surrounding eccrine glands (13 163 studies, Supplementary material tables S1 and S2), b) associated with elastic fibers (12 studies), c) in 164 connection with collagen matrix/fibers (10 studies), d) surrounding small blood vessels (9 studies), and e) 165 intracellular (8 studies). Regarding intracellular localization, this occurred inside fibroblasts (4 studies) and 166 macrophages (2 studies) (Supplementary material tables S1 and S2). Subcellular localization was described 167 as inside lysosomes and free in the cytoplasm (Rongioletti et al., 1992) . In eyes, deposited particles were 168 detected in the cornea, conjunctiva (Rungby, 1986) , and other anatomical structures (Supplementary material 169 table S1). 170
Deposited particles, in addition to silver, have also been reported to contain other elements. In 171 generalized and localized argyria, deposited particles have been reported to contain a) silver and sulfur 172 (Buckley et al., 1965; Schlötzer-Schrehardt et al., 2001) ; b) silver and selenium (Loeffler and Lee, 1987; Jan 173 Aaseth et al., 1981) ; and c) silver, sulfur, and selenium (Bleehen et al., 1981; Karcioglu and Caldwell, 1985; 174 Matsumura et al., 1992; Suzuki et al., 1993) . The presence of sulfur in the deposited particles can be 175 explained by the strong affinity of silver to sulfur by the Ag-thiolate binding (Massi and Santucci, 1998) . The 176
formed Ag 2 S is chemically stable and highly insoluble in water (Liu et al., 2010) . It has been suggested that
sulfur in the deposited particles over time is substituted by selenium to form silver selenide (Massi and 178 Santucci, 1998; Sato et al., 1999) . Silver selenide is chemically more stable than silver sulfide and of even 179 lower solubility. Additionally, the direct binding of silver to selenium in the enzyme glutathione peroxidase 180 leading to the direct formation of the chemically stable and inert compound silver selenide has been 181 suggested (Massi and Santucci, 1998) . The serum level of selenium in patients with argyria was the most 182 critical factor for the presence or absence of selenium within the silver-containing deposited particles, 183 whereas no relation was observed for factors such as age; sex; the amount, duration, and route of silver 184 introduced; or the different tissues and organs biopsied (Sato et al., 1999) . The formation of the insoluble 185 silver sulfide and silver selenide have been suggested to reduce the toxic effects of silver ions by reducing 186 their biological availability (Massi and Santucci, 1998; Sato et al., 1999) . Notably, a range studies, including 187 oral exposure studies, case studies with acupuncture needle implantations, and some occupational studies, 188 have also demonstrated the deposition of silver and selenium with chloride mercury, titanium, iron, nickel, 189 sulfur, and osmium (Berry et al., 1995; Berry and Galle, 1982; Bleehen et al., 1981; Matsumura et al., 1992; 190 Sato et al., 1999; Suzuki et al., 1993; Tanita et al., 1985; . respectively (Payne et al., 1992) . A woman used silver-containing nose drops for 10 years and had a plasma 210 level of 63 µg silver/L that decreased to 20 µg/L 6 months after discontinuation (Van de Voorde et al., 2005) . 211
In burn wound patients treated with nanocrystalline silver dressing, the mean serum level of silver was 79 212 µg/L decreasing to 9.7 µg/L and 2.0 µg/L, 3 and 6 months after discontinuation, respectively (Vlachou et al., 213 2007) . Patients with burn wounds were treated with silver nanocrystalline dressings for 9 days. This resulted 214 in a plasma level of 200 µg silver/L that decreased to 8.2 µg/L 154 days after discontinuation (Moiemen et 215 al., 2011). 216 Collectively, these data suggest that the process of silver elimination from the blood is prolonged, 217 occurring over the duration of 200 days or more. This phenomenon could be explained by slow excretion or 218 the continuous mobilization of silver from deposits in tissues. 219 220 2.3.2. Urinary and fecal excretion of silver 221 A normal urinary excretion rate was reported to be 2 µg silver/day (~1 µg/L) (Wan et al., 1991) . In a patient 222 where silver nitrate was applied for a third degree burn wound covering 96% of the body surface, the urine 223 level of silver was 38 µg/L (Bader, 1966) . In burn wound patients treated with silver sulfadiazine for various 224 time periods, a urinary threshold level was found at a serum silver level of 100 µg/L: below this serum level, 225 urinary silver was constantly low (<15 µg/L), and above this serum level, urinary silver was constantly high 226 (>50 µg/L) (Coombs et al., 1992) . In burn patients treated with silver sulfadiazine cream for 10 days, the 227 mean plasma level of silver was 200 µg/L and urinary excretion rate was 100 µg silver/day (~50 µg/L) (Wan 228 et al., 1991) . In a 61-year-old woman, leg wounds were treated for 3 weeks with 200 g silver sulfadiazine 229 cream per day. The urine level of silver was 148 µg/L (Chaby et al., 2005) . In burn patients treated with 1% 230 silver sulfadiazine cream for up to 70 days, the urinary peak silver excretion was 1,100 µg/day (~550 µg/L) 231 (Boosalis et al., 1987) . Human burns were treated with nanocrystalline silver dressing for 7 days, and a 232 plasma level of 107 µg/L was accompanied by a urinary level of 28 µg/L (Trop et al., 2006) . Pigs with scalds
were applied a 1% silver sulfadiazine cream and silver was detected in bile (0.01 % of the dose), feces 234 (0.02%-0.07% of the dose), and urine (0-0.02 % of the dose) (Lazare et al., 1974) . 235
In summary, urinary excretion has been observed in humans. In addition, studies in animals have 236 suggested fecal excretion as an accompanying pathway. 237 238 3. General toxicity -mortality and body weight loss 239 A pregnant woman had as an abortion procedure 7 g of silver nitrate (~64 mg silver/kg bw) applied in a 7% 240 water solution by intrauterine administration and died 3½ hours later with symptoms of acute circulatory 241 insufficiency. The postmortem examination showed erosion of labia paudendi, vagina, uterus, placenta and 242 of the foetus. Histopathological findings were described as: Acute ingestion of the lungs, kidneys and central 243 nervous system, as well as pulmonary edema and erosion of the uterine mucosa (Reinhardt et al., 1971) . 244
Burn wound patients were treated with 0.5% silver nitrate solution (2 kg/day/patient, ~90 mg silver/kg 245 bw/day) for an unspecified period of exposure, 5 and no toxicity was observed (Bouterie and McLean, 1971) . 246
Guinea pigs were applied 50 mg of silver as a silver nitrate skin depot (~130 mg silver/kg bw); 8 weeks later, 247 weight loss was observed. In comparison, mercuric chloride and cobalt chloride at the same molar dose 248 caused death to more than half of the animal sample (Wahlberg, 1965) . Guinea pigs were dermally exposed 249 to a suspension containing 10-20 nm silver nanoparticles for a time period of 24 h. At the investigated doses, 250 0.04, 0.2, or 400 mg/kg bw, no effects were observed (Maneewattanapinyo et al., 2011) . Similarly, no signs 251 of toxicity were observed in rats following 24 h of dermal exposure to a suspension containing 10 nm silver 252 nanoparticles at a dose of 2,000 mg silver/kg (likely per kg bw) (J. S. . 253 254 5 For one patient, the period was reported to be 56 days.
Argyria has been described as blue-gray discoloration of the skin due to the deposition of silver. Argyria can 256 be localized to the points of exposure (localized argyria) or, with higher exposure, be generalized and 257 involve areas not directly exposed. 258 259 4.1. Localized argyria 260 A patient troubled by balanitis applied silver sulfadiazine cream intermittently for 15 years, resulting in 261 localized argyria on the penis (Griffiths et al., 2006) . A surgery wound was applied silver sulfadiazine and 262 localized argyria was observed (Fisher et al., 2003) . Ocular instillation of silver nitrate instillation caused 263 argyria in the eye (Bartley, 1991) , and the use of silver-containing eye drops for many years resulted in 264 argyria of the lacrimal sac (Loeffler and Lee, 1987) . 265
Regarding metallic silver, one silversmith had argyria in the fingers (Kamiya et al., 2011) and another in 266 the fingers and arm (García-Martínez et al., 2016) . Localized argyria was observed in jewelry manufacturers, 267 in skin (Robinson-Bostom et al., 2002) and eyes (Tendler et al., 2017) following the occupational handling 268 of silver (Nagano et al., 2016) and after exposure to mirror fragments (Hristov et al., 2011) . A 40-year-old 269 woman developed argyria following the accidental imbedding of an acupuncture needle 7 years earlier (Park 270 et al., 2018) . A teenage girl had toxic epidermal necrolysis involving almost 100% of the body surface. She 271 was treated with nanocrystalline silver dressing for an unspecified period, and 4 years later, localized argyria 272 was observed (Shaub et al., 2014) . A 50-year-old silversmith had approximately 70 blue macules scattered 273 on his face, limbs, and trunk. These contained silver, sulfur, chloride, phosphorous, silicium, aluminum, 274 calcium, and potassium. The macules corresponded to sites where silver wires would puncture his skin 275 (Rongioletti et al., 1992) . 276
A range of cases have reported localized argyria but without testing for the presence of silver in the 277 tissue, including cases with dermal exposure to metallic silver (Ferrara et al., 2018; Kapur et al., 2001; 278 Morton et al., 1996; Palamar, 2010; Shall et al., 1990; Sugden et al., 2001; Utikal et al., 2006; van den 279 Nieuwenhuijsen et al., 1988) and in the eye after exposure to silver nitrate-coated soft lenses (Hau and Tuft, ). In addition, localized argyria was suggested in a burn patient treated for 10 days with nanocrystalline 281 silver dressing (~2 mg silver/kg bw/day 6 ) (Zweiker et al., 2014) . 282 Generalized argyria developed in a patient with oral ulcers who had her tongue painted with 10% silver 287 nitrate repeatedly for 1 year (~0.2 mg/kg bw/day 7 ) (Lee and Lee, 1994) . Another case was in a 58-year-old 288 woman who, because of nasal obstruction, had been using silver vitellinate-containing nose drops for 10 289 years: her serum level was 63 µg silver/L ( Van de Voorde et al., 2005) . Another case with the use of silver-290 containing nose drops was reported by (Massi and Santucci, 1998) . A 58-year-old man with chronic 291 laryngitis had self-administered silver over 15 years in the form of a spray containing argento-mercapto-3-292 hydroxy-2-propane-sodium-sulfonate and m-acetyl-amino-p-hydroxy-phenyl-sodium-arsenate. The 293 combined cumulative intake of the 2 compounds was estimated to be 360 g. A diffuse blue-gray coloration 294 of the skin was noticed. The patient died of small cell anaplastic lung carcinoma, and at autopsy, a frank dark 295 coloration of the renal cortex and choroid plexuses was observed. Silver-containing black granules were 296 detected in all investigated organs except the brain parenchyma (Gherardi et al., 1984) . Other cases in which 297 generalized argyria were confirmed by the detection of silver in biopsies were a case of using a silver foil-298 coated mouth refresher over a duration of 20 years (Sato et al., 1999) , and a case in a plating factory 299 employee (Matsumura et al., 1992) . 300 301 6 The dose was calculated based on an expected release of 1 mg silver/cm 2 and a bw of 70 kg. The dressing was changed every 3 days. 7 The dose was estimated using an assumed volume of 0.5 mL applied twice a week. A 46 year-old woman was extremely pigmented after using silver nitrate for bleeding gingiva 3 times per 304
week for 26 months. In a liver biopsy, silver colored pigment was observed in portal areas and around central 305 veins. Over the next 2 years, no substantive decrease in skin pigmentation level was observed. At subsequent 306 abdominal surgery, the pancreas, stomach, hepatic capsule, spleen, intestines, and peritoneum were all 307 discolored in a manner similar to the skin. The pancreas was, by far, the most pigmented and appeared silver 308 colored. Gastric biopsy revealed deposition of what was designated as silver granules in the connective tissue 309 (Marshall and Schneider, 1977) . Nose drops containing 20% silver iodide 6 times a day for 9 years caused 310 generalized argyria in a 69 year-old man (~0.5 mg silver/kg bw/day 8 ) (Rich et al., 1972) . Another case of 311 argyrosis was in a 45-year-old male who had performed intranasal administration of 10% silver nitrate, or so-312 called Argyrols, 9 for 17 years, using a total volume of ~30 mL/week (i.e., combined volume of the 2 313 preparations) (Kleckner Jr., 1949) . A 25-year-old woman with severe generalized dystrophic epidermolysis 314 bullosa was, since early childhood, treated with 1% silver sulfadiazine cream and had developed generalized 315 argyria. The serum level of silver was 283 µg/L (~0.1 mg silver/kg bw/day) (Flohr et al., 2008) . A 23-year-316 old patient with the same condition was treated, since birth, with applications of silver sulfadiazine cream to 317 denuded areas 2-3 times a day (~0.1 mg/kg bw/day), resulting in argyria with a serum level of 130 µg 318 silver/L (Browning and Levy, 2008) . 319
A 58-year-old man had his throat painted with mild silver protein repeatedly from the age of 3 to 12 and 320 occasionally used silver protein-containing nose drops. Generalized argyria developed in childhood, but as 321 he grew up, the abnormal color became less apparent (Pariser, 1978) . A 81-year-old woman had developed 322 generalized argyrosis 40 years earlier when treated for sinusitis with Argyrol for 2 years (Rosenblatt and 323 8 The dose was estimated using an assumed nose drop volume of 0.05 mL applied 6 times per day. 9 So-called silver protein in the form of Argyrol, according to Lancaster, was introduced in 1902 and produced by extracting gliadin from wheat and treating it under pressure in an autoclave, obtaining a white granular precipitate reported to be the nature of a vitellin. When this protein is combined with silver, the resulting product is a dark brown powder containing 30% metal. According to other accounts, the so-called vitellin is obtained from serum albumen by hydrolysis (Lancaster, 1920) , and it has been reported that the metal constitutes only 20% of the preparation (Marshall and Neave, 1906) .
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16 Cymet, 1987) . Generalized argyria also occurred in a 42-year-old man who had used 2, 10 mL bottles of 324 silver-containing nose drops weekly over the past 4 years to ameliorate allergic rhinitis. One drop contained 325 0.85 mg of silver protein (Tomi et al., 2004) . 326
Regarding nanosilver, a 17-year-old male with 30% mixed depth burns was treated for 1 week with 327 nanocrystalline silver dressing (~35 mg silver/kg bw/day). Generalized argyria was suggested based on a 328 grayish discoloration of the face. The plasma silver was 107 µg/L (Trop et al., 2006) . A patient with toxic 329 epidermal necrolysis covering 70% of the body surface was treated with 8,000 cm 2 of a silver sulfate-330 containing dressing 10 for 7 days. Argyria covering a large part of the body surface was reported. A peak 331 serum level of silver was 249 µg/L. The patient developed multiorgan system dysfunction and eventually 332 died (McCague and Joe, 2015) . 333 334 4.3. Is argyria a transient or permanent condition? 335 Argyria has been described as a persistent condition. In one case, argyria in connection with the use of silver 336 sulfadiazine cream did not diminish over 3 years (Fisher et al., 2003) . Some cases, however, have observed 337 argyria to be reversible. Localized argyria disappeared 3 years after the discontinuation of exposure to 338 nanocrystalline silver (Zweiker et al., 2014) , and generalized argyria following one week of nanocrystalline 339 silver dressing was reversible (Trop et al., 2006) . The insolubility of compounds of silver in combination 340 with other elements, as previously described, might explain the irreversibility of the coloration of the skin in 341 some patients with argyria (Sato et al., 1999) . 342 343 4.4. Summary of argyria data 344 Localized argyria has been reported with exposure to silver ions, metallic surfaces, and nanocrystalline 345 silver. Generalized argyria has been observed with ionic and nanocrystalline silver in humans at cumulative 346 doses in the range of 70 to 1500 mg silver/kg body weight (Browning and Levy, 2008; Flohr et al., 2008; 347 10 Mepilex Ag Dressing has been reported contain a silver sulfate preparation that releases silver nanoparticles into wounds (Gee Kee et al., 2013) . Kleckner Jr., 1949; Lee and Lee, 1994; Rich et al., 1972) . Regarding serum silver levels associated with 348 generalized argyria, these are in the range of 63-283 µg/L (Browning and Levy, 2008; Flohr et al., 2008; 349 Trop et al., 2006; Van de Voorde et al., 2005) . Humans in which no argyria was reported had silver serum 350 levels in the range of 0-300 µg/L (Moiemen et al., 2011; Vlachou et al., 2007; Wan et al., 1991) . In a controlled clinical trial with 24 patients on topical silver sulfadiazine with standard gauze dressings, no 356 contact dermatitis was recorded (Genuino et al., 2014) . No irritation was found in rabbits having 0.5 mL of a 357 21% 10 nm silver nanoparticle solution applied to 6 cm 2 of skin for 4 h (~16 mg silver/cm 2 ) (J. S. Kim et al., 358 2013) . Pigs were applied with 20 and 50 nm silver nanoparticles at doses of 0.34 or 34 µg/mL/day for 14 359 days (~0.06 and 6 µg silver/cm 2 ). No gross irritation was observed, but microscopic and ultrastructural 360 observations showed areas of focal inflammation at a high dose and intracellular edema at a low dose 361 (Samberg et al., 2010) . In rabbits, a 100 cm 2 dressing of cotton fabric containing a 2% silver nanoparticles 362 dispersion was dermally applied. The silver preparation was classified as a barely perceptible irritant (Zelga 363 et al., 2016) . In rabbits, different silver salts were applied to the eyes. All investigated salts, namely, silver 364 nitrate, silver ammonium nitrate, silver ammonium sulfate, and silver ammonium lactate, were found to 365 irritate eyes (Calvery, 1941) . Further, a 100 mg of 10 nm silver nanoparticles in 21% solution was applied to 366 one eye of rabbits (~5 mg silver/cm 2 ). Following 3 days of observation, no signs of irritation to the cornea, 367 iris, or conjunctiva were observed (J. S. . Silver metal disks and a silver nitrate solution were patch tested, each on the skin of 50 humans having hand 372 dermatitis. Sensitivity was detected in one patient who was exposed to both silver nitrate and silver metal 373 (Gaul, 1954) Ozkaya reported a case of allergic contact dermatitis from silver nitrate in a patch test marker 374 (Ozkaya, 2009) . A patient suspected of having a sensitivity reaction to silver sulfadiazine was found to be 375 sensitive to silver nitrate (Fraser-Moodie, 1992) . Positive patch tests for silver nitrate were observed in 2 out 376 of 118 patients with oral lichenoid lesions topographically related to dental fillings (Laine et al., 1997) . In 377 patients with leg ulcers and contact dermatitis, silver nitrate was found to be an allergen in 12% of the cases 378 (Jankićević et al., 2008) . Contact dermatitis was associated with a positive patch test for silver in a 23-year-379 old man whose work involved weighing silver (Heyl, 1979) . A case of persistent periodontitis was cured by 380 replacement of all silver amalgam restorations. The patient had a history of developing a rash and swelling 381 whenever she wore jewelry containing silver. A patch test for silver nitrate was strongly positive (Catsakis 382 and Sulica, 1978) . 383
Silver nanoparticles were tested in a guinea pig skin sensitization test, and 1 in 20 animals 384 demonstrated discrete or patchy erythema, suggesting a weak skin sensitizing effect (J. S. . 385
In the same assay, a dressing of cotton fabric containing a 2% silver nanoparticles dispersion was classified 386 as a grade II mild sensitizer (Zelga et al., 2016) . 387 388 5.3. Cases in which contact dermatitis was reported but not categorized 389 A 35-year-old man was treated for a burn wound with silver sulfadiazine twice daily and developed 390 erythema. Notably, he was also treated with silver sulfadiazine 3 years earlier (McKenna et al., 1995) . 391
Dermatitis was reported following exposure to metallic silver strands incorporated in silken and woolen 392 fabric (Hollander, 1955) . Allergic contact dermatitis to silver was reported in a jeweler (Agarwal and 393 Gawkrodger, 2002) . 
Conclusion on contact dermatitis and eye irritation 396
Overall, silver is observed to have a low potential for skin irritation. Eye irritation has been demonstrated, 397 and some individuals develop allergic contact dermatitis to silver. 398 399 6. Genotoxicity and carcinogenesis 400 Silver has been reported to bind to purine and pyrimidine bases in DNA (Goff and Powers, 1975; Luk et al., 401 1975; Sabbioni and Girardi, 1977) , increasing the possibility of it interfering with the normal function of the 402 genes. 403 404 6.1. Genotoxicity studies in vitro 405 Details of in vitro genotoxicity studies are presented in Supplementary material table S3 . Overall, silver ions 406 do not indicate mutagenic activity in bacterial assays. An exception is silver iodide, exerting a minor effect in 407 the TA97 Salmonella typhimurium frameshift strain (Eliopoulos and Mourelatos, 1998) . Silver nanoparticles 408 did not indicate any mutagenic activity in Salmonella typhimurium frameshift and base-pair substitution 409 strains Guo et al., 2016 ; H. R. Li et al., 2012) . However, a negative Ames 410 test result for a nanoformulated compound must be taken with caution, because particles may not be able to 411 penetrate the bacterial cell wall (Landsiedel et al., 2009). 412 In the comet assay, silver nanoparticles induced DNA strand breaks in different cell lines (AshaRani et 413 al., 2009; Eom and Choi, 2010; Stephan Hackenberg et al., 2011; J. S. Kim et al., 2013; Souza et al., 2016) . 414 However, no effect was observed in the NT2 human testicular embryonic cell line nor in primary testicular 415 cells from mice (Asare et al., 2012) . Mouse lymphoma cells were incubated with silver nanoparticles and had 416 increased DNA strand breaks following co-incubation with oxidizing enzymes (Mei et al., 2012) . HK-2 417 immortalized human proximal tubule cells incubated with silver nanoparticles increased DNA strand breaks 418 (Kermanizadeh et al., 2013) . Silver ions were observed to increase the number of micronuclei in 2 cell lines M A N U S C R I P T
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20 (Guo et al., 2016; Li et al., 2012) . Several cell lines were incubated with silver nanoparticles and micronuclei 420 levels increased in all but one (Kruszewski et al., 2013) . 421
In chromosomal aberration assays, silver nanoparticles have been positive in 1 of 2 studies (Hackenberg 422 et al., 2011; J. S. Kim et al., 2013) . Regarding gene mutations in mammalian cells, silver ions and 423 nanoparticles have exerted a positive effect in the mouse lymphoma assay (Guo et al., 2016; Mei et al., 424 2012) . By contrast, silver nanoparticles of different sizes had no effect in the MEF-LacZ cell mutant 425 frequency assay (Park et al., 2011). 426 In summary, silver ions and silver nanoparticles do not induce mutations in bacterial assays. By contrast, 427 several studies have shown that silver nanoparticles cause primary DNA damage in different cell lines in the 428 form of DNA strand breaks. In addition, oxidative DNA damage was observed when oxidizing enzymes 429 were applied. Regarding chromosomal damage, there is an indication that both silver ions and silver 430 nanoparticles have effects. Finally, silver nanoparticles may induce mutations in mammalian cells; however 431 more studies are required for clarification. 432 433 6.2. Genotoxicity studies In vivo 434 Details of in vivo genotoxicity studies are presented in Supplementary material table S4. In jewelry workers 435 exposed to metallic silver, DNA strand breaks increased in mononuclear leukocytes (Aktepe et al., 2015) . 436
Notably, jewelry workers in addition to skin exposure may also be exposed to silver fumes. Regarding 437 nondermal pathways, rats were intravenously injected with 20 or 200 nm silver particles. Micronuclei levels 438 were increased in bone marrow cells, whereas DNA strand break levels were not (Dobrzyńska et al., 2014). 439 In mice, intravenous injection of silver ions or nanoparticles had no effect on emerging sperm cells with 440 anomalous head morphology or on DNA strand breaks in spleen cells (Ordzhonikidze et al., 2009) . In bone 441 marrow cells from mice intraperitoneally injected with silver nanoparticles, there were increased 442 chromosomal aberrations but no increase in DNA strand breaks (Ghosh et al., 2012) . Mice dosed by the 443 same route with silver iodide showed no increase in sister chromatic exchanges in P388 lymphocyte 444 leukemia cells (Eliopoulos and Mourelatos, 1998) . In rats, inhalation of silver nanoparticles induced DNA M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 21 strand breaks in lung cells , and silver nanoparticles had no effect on micronuclei levels in 446 bone marrow cells after oral dosing (Kim et al., 2008). 447 In summary, metallic silver may induce DNA strand breaks in mononuclear leukocytes. Nanoparticles 448 increased micronuclei, DNA strand breaks, and the number of sperm cells with anomalous head morphology. 449
However, additional data are required before firm conclusions can be drawn regarding the genotoxic 450 potential of silver in vivo. 451 452 6.3. Carcinogenesis
453
Mice received a dermal application of a 10% silver nitrate solution twice a week for 20 weeks. 7,12-454 Dimethylbenz[a]anthracene (DMBA) was used as a tumorigenic inducer. There was no promotion of 455 hyperplasia (Frei and Stephens, 1968) . In a similar study design, silver nitrate was dosed twice weekly for 44 456 weeks. Three out of 22 mice bore a total of 8 papillomas; however, when a single application of croton oil 457 (5%) was interspersed between DMBA and silver nitrate, 6 out of 20 mice developed a total of 14 tumors, 1 458 of which was a carcinoma (Saffiotti and Shubik, 1963) . Rats had 1.5 cm disks of silver or tin foil embedded 459 in their abdominal wall. Following a latent period of 275-625 days, 14 tumors (32%) were found in the 460 silver group. No tumors were found in the tin group. The silver disks were intact, whereas the tin had broken 461 up and crumbled into a fragmentary mass. It was discussed whether the physical nature of the disks caused 462 the tumors and not the chemical nature of silver (Oppenheimer et al., 1956) . Silver, gold, or platinum disks 463
(1 mm 2 in area) were subcutaneously implanted in rats. No sarcomas were observed at 18 months of 464 exposure (Nothdurft, 1958) . Rats were injected with 2.5 mg colloidal silver per week for 7 months (~1.4 465 mg/kg bw/day). Argyria developed after 6-8 weeks, and at the end of the 7-month period, 6 out of 26 466 animals had tumors (spindle cell sarcomas) at the injection site (Schmãhl and Steinhoff, 1960) . Rats were 467 intramuscularly injected with so-called 300 mesh fine silver powder (5 injections of 5 mg followed by 5 468 injections of 10 mg, ~600 mg/kg bw). The rats were observed for 24 months and silver was not carcinogenic. 469
The positive control, cadmium, was carcinogenic (Furst and Schlauder, 1978) . In summary, the findings point in different directions, and additional studies on are required before a 471 firm conclusion can be drawn regarding whether silver is carcinogenic. 472 473 7. Other toxicological endpoints 474 7.1. Neurotoxicity
475
A 59-year-old man was treated for ulcers with silver sulfadiazine at a dose of 1 mg silver/kg bw/day every 476 second day for 5 months (cumulative dose: 160 mg silver/kg bw). Sensation loss was noted over the 477 forearms and legs (Payne et al., 1992) . A woman with generalized dystrophic epidermolysis bullosa was 478 treated with silver sulfate cream over the course of many years (~0.1 mg silver/kg bw/day). She developed a 479 loss of proprioception, a tingling sensation in her limbs, and impaired coordination (Flohr et al., 2008) . 480 481 7.2. Hepatic toxicity 482 Burn patients treated with silver sulfadiazine for various time periods had elevated liver enzyme activities 483 that correlated to serum levels of silver (Coombs et al., 1992) . A 17-year-old male burn patient was treated 484 with nanocrystalline silver dressing for one week with (~35 mg silver/kg bw/day). Liver enzymes were 485 upregulated during exposure but normalized upon discontinuation of the dressing (Trop et al., 2006) . 486 487 7.3. Renal toxicity 488 Following the treatment of burns with a 0.5% silver nitrate solution, argyria with depletion of body sodium 489 chloride was observed in 1 out of 15 patients (Moyer et al., 1965) . Renal dysfunction developed in a woman 490 treated with 100 g of 1% silver sulfadiazine cream per week for 18 months (~0.6 mg/kg bw/day or a 491 cumulative dose of ~325 mg/kg bw). The level of silver in blood was 38 µg/L. However, a female burn 492 wound patient treated with silver sulfadiazine and having a silver blood concentration of 440 µg/L had 493 normal renal function (Maitre et al., 2002) . A burn wound developing after the spraying of a ruptured 494 conduit that contained 60% sulfuric acid and 40% nitric acid at 60°C was treated with silver sulfadiazine for M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 23 60 days, during which nephrotic syndrome developed. Improved renal function and remission of proteinuria 496 occurred after 5 months of therapy with immunosuppressive agents (Owens et al., 1974) . A 61-year-old 497 woman with ulcers was treated with 200 g of silver sulfadiazine cream daily for 3 weeks and developed renal 498 failure (~180 mg silver/kg bw). The blood level of silver was 196 µg/L. The signs regressed upon withdrawal 499 of the cream and after several sessions of hemodialysis (Chaby et al., 2005) . A woman with a burn covering 500 70% of the total body surface area was treated with 8,000 cm 2 silver-containing silicone foam dressing for 7 501 days and developed kidney failure. She subsequently developed multiorgan system dysfunction and 502 eventually died (McCague and Joe, 2015) . 503 504 7.4. Hematological toxicity 505 There are several reports that indicate leukopenia is associated with the use of silver sulfadiazine in humans 506 (Caffee and Bingham, 1982; Chaby et al., 2005; Chan et al., 1976; Fraser and Beaulieu, 1979; Gbaanador et 507 al., 1987; Jarrett et al., 1978; Lockhart et al., 1983; Valente and Axelrod, 1978; Viala et al., 1997; Wilson et 508 al., 1986) . In support of this assertion, silver sulfadiazine was applied to mice with full-thickness skin 509 excision covering 10% of the body surface, resulting in a reduction in total peripheral blood leukocyte counts 510 (Gamelli et al., 1993) . The findings of 2 controlled human studies have not supported that silver sulfadiazine 511 induces leukopenia (Kiker et al., 1977; Thomson et al., 1989) , and neutropenia sometimes occurs as an 512 adverse effect of sulfadiazine in the absence of silver (Chen et al., 1991; Finland et al., 1984; Marshall et al., 513 1950; McMillin, 1951; Trepanier, 2004) . However, in absence of sulfadiazine, leukopenia was reported in a 514 burn patient treated with a silver-containing silicone foam dressing for 7 days (McCague and Joe, 2015) . 515
Methemoglobinemia secondary to dermal silver nitrate therapy has been reported 516 Cushing and Smith, 1969; Strauch et al., 1969a Strauch et al., , 1969b . Methemoglobinemia was also reported following 517 the exposure to nitrate alone; thus, nitrate and not silver may be responsible for the effect (Inoue et al., 1999) . Silver nanoparticles could be expected to act differently than silver ions: 1) they could act as a physical 521 entity, for example, by breaking a cell wall or obstructing a vessel (only free nanoparticles); 2) they could 522 provide a surface milieu in which chemical reactions could occur or molecules be absorbed and immobilized; 523 or 3) they could release ions. The release of silver ions from the surface of metallic silver has been 524 demonstrated in vivo (Danscher and Locht, 2010) . The studies described in the present review that compare 525 silver ions with nanoparticles and nanocrystalline coatings use animals and indicate a similar effect of silver 526 ions and nanoformulated silver (Guo et al., 2016; Korani et al., 2013; Li et al., 2016; Nadworny et al., 2010; 527 Ordzhonikidze et al., 2009; Pfurtscheller et al., 2014) ; and this is also observed to be the case for oral 528 exposure to silver (Hadrup et al., 2012; Hadrup and Lam, 2014) . One dermal exception is a study in which 529 skin irritation was observed with silver nanoparticles but not silver nitrate (Koohi, M K; Hejazy, M; Asadi, 530 F; Asadian, 2011) . 531 532 9. Risk characterization 533
The question is, what are the critical effects of dermal and mucosal silver? The 7 g dosage of intrauterine 534 silver nitrate as an abortion procedure caused mortality. This dose corresponds to 64 mg silver/kg bw. In 535 guinea pigs, 130 mg silver/kg bw given as a skin depot caused weight loss. Regarding generalized argyria, 536 this has been reported in humans with estimated cumulative doses as low as 70 mg/kg bw (Lee and Lee, 537 1994) . Collectively, these findings suggest that critical effects start to occur at cumulative doses in the range 538 of 60 to 70 mg silver/kg bw. Regarding the ultimate endpoint of genotoxicity and carcinogenicity, the 539 evidence is conflicting as to the role of silver; although most have been negative, more studies on the 540 carcinogenic potential would be relevant. 541 542 10. Summary including sulfur and selenium. The deposition of silver as particles causes discoloration known as argyria. 547 Excretion after exposure by the dermal and mucosal surface routes involves increased levels in urine and 548 feces. The elimination from plasma is prolonged, lasting several of hundreds of days. 549
Regarding toxicity, a case of mortality was observed at intrauterine exposure to ionic silver at 64 mg/kg 550 bw. Localized argyria has been reported with exposure to silver ions, metallic surfaces, and nanocrystalline 551 silver. Generalized argyria was observed with ionic and nanocrystalline silver in humans at cumulative doses 552 in the range of 70 to 1500 mg silver/kg body weight. Silver is observed to have a low potential for skin 553 irritation. Eye irritation and some cases of allergic contact dermatitis have been reported. Silver may cause 554 genotoxicity, but additional data are required to assess its carcinogenic potential. Other reported toxicities 555 include hepatic, renal, neurological, and hematological effects. 
Highlights
(Toxicity of silver ions, metallic silver, and silver nanoparticle materials after in vivo dermal and mucosal surface exposure: a review) 1. Silver is an ingredient in certain dermal and mucosal medical applications 2. Silver can deposit in the body as particles causing a discoloration called argyria 3. Silver is observed to have a low potential for skin irritation. Eye irritation and allergic contact dermatitis have been reported 4. Silver may cause genotoxicity, but additional data on its carcinogenic potential are required
